It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cerebrospinal fluid (CSF) plays an important role in brain tumors, including medulloblastoma (MBL). Recent advancements in mass spectrometry systems and ‘Omics’ data analysis methods enable unbiased, high proteome depth research. We conducted proteomic profiling of the total CSF in MBL patients with the purpose of finding a potential diagnostic biomarker for MBL. We quantified 1112 proteins per CSF sample. Feature selection identified four elevated soluble proteins (SPTBN1, HSP90AA1, TKT, and NME1-NME2) in MBL CSF. Validation with ELISA confirmed that TKT was significantly elevated in MBL. Additionally, TKT-positive extracellular vesicles were significantly enriched in MBL CSF and correlated with the burden of leptomeningeal seeding. Our results provide insights into the proteomics data of the total CSF of MBL patients. Furthermore, we identified the significance of TKT within the total CSF and its presence within circulating EVs in the CSF. We suggest that TKT may serve as a biomarker for MBL.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Seoul National University Children’s Hospital, Division of Pediatric Neurosurgery, Pediatric Clinical Neuroscience Center, Seoul, South Korea (GRID:grid.412482.9) (ISNI:0000 0004 0484 7305); Seoul National University College of Medicine, Department of Neurosurgery, Seoul National University Hospital, Seoul, South Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
2 Seoul National University Hospital, Proteomics Core Facility, Biomedical Research Institute, Seoul, South Korea (GRID:grid.412484.f) (ISNI:0000 0001 0302 820X)
3 Seoul National University Children’s Hospital, Division of Pediatric Neurosurgery, Pediatric Clinical Neuroscience Center, Seoul, South Korea (GRID:grid.412482.9) (ISNI:0000 0004 0484 7305); Seoul National University College of Medicine, Department of Neurosurgery, Seoul National University Hospital, Seoul, South Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Seoul National University College of Medicine, Neuroscience Research Institute, Seoul, South Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
4 Seoul National University Hospital, Proteomics Core Facility, Biomedical Research Institute, Seoul, South Korea (GRID:grid.412484.f) (ISNI:0000 0001 0302 820X); Seoul National University Hospital, Department of Transdisciplinary Medicine, Seoul, South Korea (GRID:grid.412484.f) (ISNI:0000 0001 0302 820X)